Implementing Personalized Medicine in COVID-19 in Andalusia : An Opportunity to Transform the Healthcare System
The COVID-19 pandemic represents an unprecedented opportunity to exploit the advantages of personalized medicine for the prevention, diagnosis, treatment, surveillance and management of a new challenge in public health. COVID-19 infection is highly variable, ranging from asymptomatic infections to severe, life-threatening manifestations. Personalized medicine can play a key role in elucidating individual susceptibility to the infection as well as inter-individual variability in clinical course, prognosis and response to treatment. Integrating personalized medicine into clinical practice can also transform health care by enabling the design of preventive and therapeutic strategies tailored to individual profiles, improving the detection of outbreaks or defining transmission patterns at an increasingly local level. SARS-CoV2 genome sequencing, together with the assessment of specific patient genetic variants, will support clinical decision-makers and ultimately better ways to fight this disease. Additionally, it would facilitate a better stratification and selection of patients for clinical trials, thus increasing the likelihood of obtaining positive results. Lastly, defining a national strategy to implement in clinical practice all available tools of personalized medicine in COVID-19 could be challenging but linked to a positive transformation of the health care system. In this review, we provide an update of the achievements, promises, and challenges of personalized medicine in the fight against COVID-19 from susceptibility to natural history and response to therapy, as well as from surveillance to control measures and vaccination. We also discuss strategies to facilitate the adoption of this new paradigm for medical and public health measures during and after the pandemic in health care systems.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of personalized medicine - 11(2021), 6 vom: 26. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dopazo, Joaquín [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Covid-19 |
|---|
| Anmerkungen: |
Date Revised 07.11.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jpm11060475 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326219889 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326219889 | ||
| 003 | DE-627 | ||
| 005 | 20231225194125.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jpm11060475 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1087.xml |
| 035 | |a (DE-627)NLM326219889 | ||
| 035 | |a (NLM)34073493 | ||
| 035 | |a (PII)475 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dopazo, Joaquín |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Implementing Personalized Medicine in COVID-19 in Andalusia |b An Opportunity to Transform the Healthcare System |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 07.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The COVID-19 pandemic represents an unprecedented opportunity to exploit the advantages of personalized medicine for the prevention, diagnosis, treatment, surveillance and management of a new challenge in public health. COVID-19 infection is highly variable, ranging from asymptomatic infections to severe, life-threatening manifestations. Personalized medicine can play a key role in elucidating individual susceptibility to the infection as well as inter-individual variability in clinical course, prognosis and response to treatment. Integrating personalized medicine into clinical practice can also transform health care by enabling the design of preventive and therapeutic strategies tailored to individual profiles, improving the detection of outbreaks or defining transmission patterns at an increasingly local level. SARS-CoV2 genome sequencing, together with the assessment of specific patient genetic variants, will support clinical decision-makers and ultimately better ways to fight this disease. Additionally, it would facilitate a better stratification and selection of patients for clinical trials, thus increasing the likelihood of obtaining positive results. Lastly, defining a national strategy to implement in clinical practice all available tools of personalized medicine in COVID-19 could be challenging but linked to a positive transformation of the health care system. In this review, we provide an update of the achievements, promises, and challenges of personalized medicine in the fight against COVID-19 from susceptibility to natural history and response to therapy, as well as from surveillance to control measures and vaccination. We also discuss strategies to facilitate the adoption of this new paradigm for medical and public health measures during and after the pandemic in health care systems | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a SARS CoV2 | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a host genetics | |
| 650 | 4 | |a personalized medicine | |
| 650 | 4 | |a precision medicine | |
| 650 | 4 | |a viral genome | |
| 700 | 1 | |a Maya-Miles, Douglas |e verfasserin |4 aut | |
| 700 | 1 | |a García, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Lorusso, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Calleja, Miguel Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Pareja, María Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a López-Miranda, José |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Baño, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Padillo, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Túnez, Isaac |e verfasserin |4 aut | |
| 700 | 1 | |a Romero-Gómez, Manuel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of personalized medicine |d 2011 |g 11(2021), 6 vom: 26. Mai |w (DE-627)NLM228113881 |x 2075-4426 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:6 |g day:26 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jpm11060475 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 6 |b 26 |c 05 | ||